Quipt Home Medical (QIPT – Research Report) has received a rating update from a Wall Street analyst today. The Healthcare company, Quipt Home Medical (TSX: QIPT) has just received a rating update from a Wall Street analyst.
According to TipRanks.com, Quenneville is a 1-star analyst with an average return of -2.9% and a 30.6% success rate. Quenneville covers the Healthcare sector, focusing on stocks such as Cognetivity Neurosciences, Antibe Therapeutics, and Valeo Pharma.
Currently, the analyst consensus on Quipt Home Medical is a Strong Buy with an average price target of C$14.59.
Based on Quipt Home Medical’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of C$58.12 million and GAAP net loss of C$749K. In comparison, last year the company earned revenue of C$33.55 million and had a net profit of C$5.03 million.
Protech Home Medical Corp provides in-home monitoring equipment, supplies and services to patients. The company’s services consist of Daily & Ambulatory Aides, Power Mobility, INR Self-Testing, Respiratory Equipment Rental, Home ventilation, Oxygen Therapy, and Sleep Apnea & PAP Treatment.
The company’s shares closed last Tuesday at C$7.26.
Read More on TSE:QIPT:
- Quipt Home Medical Reports Strong Operational Performance With Record Third Quarter Fiscal 2023 Financial Results Posting Revenue Growth of 64% and Adjusted EBITDA Growth of 80%
- Is QIPT a Buy, Before Earnings?
- Quipt Home Medical to Participate at the 43rd Annual Canaccord Growth Conference
- Quipt Home Medical Announces Up-listing to the Toronto Stock Exchange
- Quipt Home Medical announces up-listing to the Toronto Stock Exchange
